Another clinical trial: GLP1R in Parkinso... - Cure Parkinson's

Cure Parkinson's

26,300 members27,659 posts

Another clinical trial: GLP1R in Parkinson's Disease (GIPD)

Farooqji profile image
0 Replies

Semaglutide is a synthetic analogue of glucagon-like peptide 1 (GLP1), which stimulates GLP1 receptors (GLP1R). Stimulation of GLP1R in B-cells in the pancreas potentiates insulin secretion and contribute to blood glucose regulation. In the brain it is known that GLP1R stimulation in the hypothalamus contribute to appetite and body weight regulation. Besides these known GLP1R effects, GLP1R can inhibit production of pro-inflammatory cytokines in microglia, which in turn will stop/slow down degeneration of neurons in the brain. Another GLP1 agonist, exenatide, has been tested in patients with PD, showing significant improvement of motor symptoms. However, it could not be concluded whether this was caused by an symptomatic or neuroprotective effect.

clinicaltrials.gov/ct2/show...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Management of Parkinson's Disease?

In this Neuro Support Group on 1/19/22, Dr. Ryan Kochanski discussed the use of Asleep MRI-Guided...

Parkinson's Disease: emerging treatment target, the NLRP inflammasome.

Hyperstimulated immune cells in the brain are emerging as a hallmark feature of most...

Study: Deep brain stimulation may slow Parkinson's disease

OK, here is a reason to get DBS without waiting until meds don't work....

Parkinson's disease is an autoimmune disease: An emerging viewpoint

The first description of Parkinson's disease (PD) was made in 1817 by James Parkinson. In his first...

Terazosin for Parkinson's Disease (TZ-PD) Trial

Terazosin ========= Somebody in a different forum posted that the best medicine they are taking for...